Sustained-release buprenorphine solutions
The disclosure provides extended release pharmaceutical formulations comprising an opioid, particularly buprenorphine, a biocompatible organic solvent, and, optionally, a glycol, for use in the treatment of pain or opioid dependence. The pharmaceutical formulations are in the form of a pharmaceutical solution.
1. A pharmaceutical solution consisting of:
(i) at least 8 wt % buprenorphine in the form of a free base or a pharmaceutically acceptable salt, and
(ii) N-methyl-2-pyrrolidone, dimethyl acetamide, dimethyl sulfoxide, or a combination of two or more thereof.
2. The solution of claim 1 , wherein the buprenorphine is present in an amount of about 10 wt % to about 55 wt %.
3. A pharmaceutical solution comprising:
(i) at least 8 wt % buprenorphine in the form of a free base or a pharmaceutically acceptable salt;
(ii) N-methyl-2-pyrrolidone, dimethyl acetamide, dimethyl sulfoxide, or a combination of two or more thereof; and
(iii) polyethylene glycol in an amount from about 20% by weight to about 60% by weight of the mixture of (ii) and (iii).
4. The solution of claim 3 , wherein the polyethylene glycol is present in an amount from about 20% by weight to about 40% by weight of the mixture of (ii) and (iii).
5. The solution of claim 3 , wherein the weight ratio of (ii) to (iii) is from 0.4:1 to 4:1.
6. The solution of claim 3 , wherein the weight ratio of (ii) to (iii) is from 1:1 to 1.5:1.
7. The solution of claim 3 , wherein the weight ratio of (i) to (iii) is from 0.15:1 to 5:1.
8. The solution of claim 3 , wherein the weight ratio of (i) to (iii) is from 0.5:1 to 1:1.
9. The solution of claim 3 , wherein the buprenorphine is present in an amount of about 10 wt % to about 55 wt %.
10. The solution of claim 3 , wherein the buprenorphine is present in an amount of about 15 wt % to about 50 wt %.
11. The solution of claim 3 , wherein the polyethylene glycol has an average molecular weight of about 100 to about 1,000.
12. The solution of claim 11 , wherein the polyethylene glycol has an average molecular weight of about 300 or about 400.
13. The solution of claim 3 , wherein (ii) is N-methyl-2-pyrrolidone.
14. An injectable pharmaceutical solution comprising:
(i) about 15 wt % to about 55 wt % of buprenorphine in the form of a free base or a pharmaceutically acceptable salt;
(ii) N-methyl-2-pyrrolidone, dimethyl acetamide, dimethyl sulfoxide, or a combination of two or more thereof; and
(iii) polyethylene glycol, propylene glycol, or a combination thereof;
wherein the weight ratio of (i):(ii):(iii) is from about 1:2.7:6.3 to about 1:0.74:0.08.
15. The solution of claim 14 , wherein (iii) is polyethylene glycol having an average molecular weight of about 100 to about 1,000.
16. The solution of claim 14 , wherein the weight ratio of (i):(ii):(iii) is 1:2:2 to 1:1:0.4.
17. The solution of claim 14 , wherein (i) is buprenorphine in the form of the free base, (ii) is N-methyl-2-pyrrolidone; and (iii) is polyethylene glycol having an average molecular weight of about 300 or about 400.
18. The solution of claim 14 consisting of (i), (ii), and (iii).
19. The solution of claim 14 , wherein (i) is buprenorphine in the form of the free base, (ii) is N-methyl-2-pyrrolidone, and (iii) is polyethylene glycol.
20. A method of treating opioid dependence or pain in a patient in need thereof comprising administering a therapeutically effective amount of the pharmaceutical solution of claim 3 to the patient to treat the opioid dependence or pain.
21. The method of claim 20 , wherein the solution is administered to the patient by subcutaneous injection once per month.
22. The method of claim 20 , wherein the solution is administered to the patient by subcutaneous injection once every three months.
23. The method of claim 20 for treating opioid dependence.
24. The solution of claim 3 , wherein the buprenorphine is in the form of the free base.
25. The solution of claim 14 , wherein (ii) is N-methyl-2-pyrrolidone.
26. The solution of claim 3 , comprising (i) about 30 wt % to about 50 wt % of buprenorphine in the form of the free base; (ii) N-methyl-2-pyrrolidone; and (iii) polyethylene glycol, wherein the polyethylene glycol is present in an amount of about 20 wt % to about 40 wt % of the mixture of (ii) and (iii).
27. The solution of claim 26 , wherein the polyethylene glycol has an average molecular weight of about 300 or about 400.
28. The solution of claim 3 , comprising (i) about 20 wt % to about 55 wt % of buprenorphine in the form of the free base; (ii) N-methyl-2-pyrrolidone; and (iii) polyethylene glycol, wherein the polyethylene glycol is present in an amount of about 20 wt % to about 40 wt % of the mixture of (ii) and (iii).
29. The solution of claim 28 , wherein the polyethylene glycol has an average molecular weight of about 300 or about 400.
30. The solution of claim 3 , wherein the weight ratio of (ii) to (iii) is 0.65:1 to 2.5:1.
31. The solution of claim 3 , wherein the weight ratio of (i) to (iii) is 0.4:1 to 3.5:1.
32. The solution of claim 3 , wherein the polyethylene glycol has an average molecular weight of about 200 to about 500.
33. The solution of claim 14 , wherein (i) is buprenorphine in the form of the free base; (ii) is N-methyl-2-pyrrolidone, and (iii) is polyethylene glycol.
34. The solution of claim 14 , wherein the weight ratio of (ii) to (iii) is from 0.4:1 to 4:1.
35. The solution of claim 14 , wherein the weight ratio of (ii) to (iii) is 0.65:1 to 2.5:1.
36. The solution of claim 14 , wherein the weight ratio of (i) to (iii) is from 0.15:1 to 5:1.
37. The solution of claim 14 , wherein the weight ratio of (i) to (iii) is 0.4:1 to 3.5:1.
38. A method of treating opioid dependence or pain in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of the solution of claim 14 to treat the opioid dependence or pain.
39. The method of claim 38 , wherein the solution is administered to the patient once per month by subcutaneous injection to treat opioid dependence.
40. A method of treating opioid dependence or pain in a patient in need thereof, the method comprising subcutaneously injecting into the patient a therapeutically effective amount of a solution to treat the opioid dependence or pain; wherein the solution comprises (i) buprenorphine in the form of a free base or a pharmaceutically acceptable salt; (ii) N-methyl-2-pyrrolidone, dimethyl acetamide, dimethyl sulfoxide, or a combination of two or more thereof; and (iii) polyethylene glycol, propylene glycol, or a combination thereof.
41. The method of claim 40 , wherein the solution is administered to the patient once per month or once every three months.
42. The method of claim 40 for treating opioid dependence.
43. The method of claim 40 , wherein the solution comprises: (i) buprenorphine in the form of the free base; (ii) N-methyl-2-pyrrolidone; and (iii) polyethylene glycol.
44. A pharmaceutical solution consisting essentially of:
(i) at least 8 wt % buprenorphine in the form of a free base or a pharmaceutically acceptable salt;
(ii) N-methyl-2-pyrrolidone, dimethyl acetamide, dimethyl sulfoxide, or a combination of two or more thereof; and
(iii) polyethylene glycol.
45. The pharmaceutical solution of claim 44 , consisting of (i), (ii), and (iii).
46. A pharmaceutical solution comprising:
(i) buprenorphine in the form of a free base or a pharmaceutically acceptable salt;
(ii) N-methyl-2-pyrrolidone, dimethyl acetamide, dimethyl sulfoxide, or a combination of two or more thereof;
(iii) polyethylene glycol, propylene glycol, or a combination thereof;
wherein the weight ratio of (i):(ii):(iii) is from 1:2.7:6.3 to 1:0.74:0.08; and
wherein the pharmaceutical solution does not comprise a biodegradable polymer.
47. The pharmaceutical solution of claim 46 , wherein the biodegradable polymer comprises a polyester, a polylactide, a polyglycolide, a polycaprolactone, a polyanhydride, a polyamide, a polyurethane, a polyesteramide, a polydioxanone, a polyacetal, a polyketal, a polycarbonate, a polyorthocarbonate, a polyorthoester, a polyphosphoester, a polyphosphazene, a polyhydroxybutyrate, a polyhydroxyvalerate, a polyalkylene oxalate, a polyalkylene succinate, a poly(malic acid), a poly(amino acids), copolymers, terpolymers, combinations, or mixtures thereof.
48. A pharmaceutical solution comprising:
(i) at least 8 wt % buprenorphine in the form of a free base or a pharmaceutically acceptable salt;
(ii) N-methyl-2-pyrrolidone, dimethyl acetamide, dimethyl sulfoxide, or a combination of two or more thereof; and
(iii) polyethylene glycol;
wherein the pharmaceutical solution does not comprise a biodegradable polymer.
49. A pharmaceutical solution comprising:
(i) at least 8 wt % buprenorphine in the form of a free base or a pharmaceutically acceptable salt;
(ii) N-methyl-2-pyrrolidone, dimethyl acetamide, dimethyl sulfoxide, or a combination of two or more thereof; and
(iii) polyethylene glycol;
wherein the pharmaceutical solution does not comprise a polyester, a polylactide, a polyglycolide, a polycaprolactone, a polyanhydride, a polyamide, a polyurethane, a polyesteramide, a polydioxanone, a polyacetal, a polyketal, a polycarbonate, a polyorthocarbonate, a polyorthoester, a polyphosphoester, a polyphosphazene, a polyhydroxybutyrate, a polyhydroxyvalerate, a polyalkylene oxalate, a polyalkylene succinate, a poly(malic acid), a poly(amino acids), copolymers, terpolymers, combinations, or mixtures thereof.